Year: 2020
Type: review
Abstract: With the increasing prevalence of Parkinson's disease (PD), there is an immediate need to interdict disease signs and symptoms. In recent years this need was met through therapeutic approaches focused on regenerative stem cell replacement and alpha-synuclein clearance. However, neither have shown long-term clinical benefit. A novel therapeutic approach designed to affect disease is focused on transforming the brain's immune microenvironment. As disordered innate and adaptive immune functions are primary components of neurodegenerative disease pathogenesis, this has emerged as a clear opportunity for therapeutic development. Interventions that immunologically restore the brain's homeostatic environment can lead to neuroprotective outcomes. These have recently been demonstrated in both laboratory and early clinical investigations. To these ends, efforts to increase the numbers and function of regulatory T cells over dominant effector cells that exacerbate systemic inflammation and neurodegeneration have emerged as a primary research focus. These therapeutics show broad promise in affecting disease outcomes beyond PD, such as for Alzheimer's disease, stroke and traumatic brain injuries, which share common neurodegenerative disease processes.
Source: Neurobiology of Disease
Institution: University of Nebraska Medical Center
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,500
Awards: Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1, NanoART Manufacture, Delivery and Pharmacokinetics for Optimizing Drug Adherence, Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center, T Cell-Mediated Neurodegeneration in Parkinson's Disease, Nanomedicine and NeuroAIDS, Glutaminase and its neurotoxic link to HAND, Novel Adjunctive Therapies for NeuroAIDS, Molecular Mechanisms of HIV-1 Associated Encephalopathy, SMART HAND, Proteomic Strategies for AIDS and Drug Abuse - HIV and METH CNS Synergy, Chemical, Nanomedicine and Autophagy Strategies to Create Sustained-Release Antiretroviral Products, Neuroprotective Vaccination for Parkinson's Disease, Neural Immunity in HIV Dementia, Neuroprotective Immunity and HIV Dementia, G9000346257, G9000352132, Prodrug Formulations Create Sustained-Release Antiretrovirals, Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirs
OpenAlex ID: W3001548005